BRIEF-Roche’S Phase III Starglo Study Demonstrates Columvi Significantly Extends Survival In People June 15 (Reuters) - Roche Holding AG ROG.S : ROCHE’S PHASE III STARGLO STUDY DEMONSTRATES COLUMVI SIGNIFICANTLY EXTENDS SURVIVAL IN PEOPLE WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA STUDY MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVA

UPDATE 2-Tempus AI shares jump 8% in strong Nasdaq debut as US IPO market thaws Adds background in paragraphs 6-10 June 14 (Reuters) - Shares of SoftBank Group-backed 9984.T Tempus AI TEM.O rose 8.1% in their debut on the Nasdaq on Friday, giving the artificial intelligence-based genetic testing company a valuation of $6.6 billion. The company is among the several AI-focused firms that have garnered investors' interest, thanks to the popularity of OpenAI's viral chatbot ChatGPT.

EUROPE RESEARCH ROUNDUP-AB Dynamics, Etteplan, Wise June 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AB Dynamics, Etteplan and Wise, on Friday. HIGHLIGHTS * AB Dynamics Plc ABDP.L : Berenberg re-initiates coverage With Buy rating; PT 2,620p * Crest Nicholson CRST.L : Barclays cuts target price to 230p from 258p * Etteplan Oyj ETTE.HE : Evli Research raises to buy from hold * Halma HLMA.L : Barclays raises target price to 284

AbbVie inks immune disorder drug licensing deal with China's FutureGen June 13 (Reuters) - U.S. drugmaker AbbVie ABBV.N will develop and commercialize an experimental treatment for inflammatory bowel disease (IBD) from China's FutureGen Biopharmaceutical under a licensing agreement, the companies said on Thursday. WHY IT'S IMPORTANT AbbVie has been counting on its newer immunology medicines to help make up for declining sales of blockbuster arthritis drug Humira following the entry of biosimilar

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .